Culture-Independent Metagenomic Surveillance of Commercially Available Probiotics with High-Throughput Next-Generation Sequencing

The rapidly growing supplement industry operates without a formal premarket approval process. Consumers rely on product labels to be accurate and true. Those products containing live microbials report both identity and viability on most product labels. This study used next-generation sequencing technology as an analytical tool in conjunction with classic culture methods to examine the validity of the labels on supplement products containing live microbials found in the United States marketplace. Our results show the importance of testing these products for identity, viability, and potential contaminants, as well as introduce a new culture-independent diagnostic approach for testing these products. ABSTRACT Millions of people consume dietary supplements either following a doctor’s recommendation or at their own discretion to improve their overall health and well-being. This is a rapidly growing trend, with an associated and expanding manufacturing industry to meet the demand for new health-related products. In this study, we examined the contents and microbial viability of several popular probiotic products on the United States market. Culture-independent methods are proving ideal for fast and efficient analysis of foodborne pathogens and their associated microbial communities but may also be relevant for analyzing probiotics containing mixed microbial constituents. These products were subjected to next-generation whole-genome sequencing and analyzed by a custom in-house-developed k-mer counting method to validate manufacturer label information. In addition, the batch variability of respective products was examined to determine if any changes in their formulations and/or the manufacturing process occurred. Overall, the products we tested adhered to the ingredient claims and lot-to-lot differences were minimal. However, there were a few discrepancies in the naming of closely related Lactobacillus and Bifidobacterium species, whereas one product contained an apparent Enterococcus contaminant in two of its three lots. With the microbial contents of the products identified, we used traditional PCR and colony counting methods to comparatively assess our results and verify the viability of the microbes in these products with regard to the labeling claims. Of all the supplements examined, only one was found to be inaccurate in viability. Our use of next-generation sequencing as an analytical tool clearly demonstrated its utility for quickly analyzing commercially available products containing multiple microbes to ensure consumer safety. IMPORTANCE The rapidly growing supplement industry operates without a formal premarket approval process. Consumers rely on product labels to be accurate and true. Those products containing live microbials report both identity and viability on most product labels. This study used next-generation sequencing technology as an analytical tool in conjunction with classic culture methods to examine the validity of the labels on supplement products containing live microbials found in the United States marketplace. Our results show the importance of testing these products for identity, viability, and potential contaminants, as well as introduce a new culture-independent diagnostic approach for testing these products. Podcast: A podcast concerning this article is available.

[1]  H. Goossens,et al.  Accuracy of species identity of commercial bacterial cultures intended for probiotic or nutritional use. , 2006, Research in microbiology.

[2]  Mary Ellen Sanders,et al.  Bringing a probiotic-containing functional food to the market: microbiological, product, regulatory and labeling issues , 1999, Antonie van Leeuwenhoek.

[3]  Eoin L Brodie,et al.  PCR Amplification-Independent Methods for Detection of Microbial Communities by the High-Density Microarray PhyloChip , 2011, Applied and Environmental Microbiology.

[4]  C. Fraser,et al.  Probiotics: Finding the Right Regulatory Balance , 2013, Science.

[5]  B. Foligné,et al.  Discovering probiotic microorganisms: in vitro, in vivo, genetic and omics approaches , 2015, Front. Microbiol..

[6]  S. Zanetti,et al.  Comparison of the incidence of virulence determinants and antibiotic resistance between Enterococcus faecium strains of dairy, animal and clinical origin. , 2003, International journal of food microbiology.

[7]  Daniel B. DiGiulio,et al.  Development of the Human Infant Intestinal Microbiota , 2007, PLoS biology.

[8]  L. Drago,et al.  Microbiological Evaluation of Commercial Probiotic Products Available in the USA in 2009 , 2010, Journal of chemotherapy.

[9]  Susan R. Leonard,et al.  Application of Metagenomic Sequencing to Food Safety: Detection of Shiga Toxin-Producing Escherichia coli on Fresh Bagged Spinach , 2015, Applied and Environmental Microbiology.

[10]  J. Heimbach,et al.  Novel probiotics and prebiotics: road to the market. , 2015, Current opinion in biotechnology.

[11]  Laura Bonetta,et al.  Whole-Genome Sequencing Breaks the Cost Barrier , 2010, Cell.

[12]  C. Elkins,et al.  Development and utility of the FDA ‘GutProbe’ DNA microarray for identification, genotyping and metagenomic analysis of commercially available probiotics , 2015, Journal of applied microbiology.

[13]  J. Hamilton-miller,et al.  Deficiencies in microbiological quality and labelling of probiotic supplements. , 2002, International journal of food microbiology.

[14]  L. Dicks,et al.  Reclassification of Lactobacillus casei subsp. casei ATCC 393 and Lactobacillus rhamnosus ATCC 15820 as Lactobacillus zeae nom. rev., designation of ATCC 334 as the neotype of L. casei subsp. casei, and rejection of the name Lactobacillus paracasei. , 1996, International journal of systematic bacteriology.

[15]  M. Saxelin Probiotic formulations and applications, the current probiotics market, and changes in the marketplace: a European perspective. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  R. Knight,et al.  Microbial community profiling for human microbiome projects: Tools, techniques, and challenges. , 2009, Genome research.

[17]  E. Hayden Is the $1,000 genome for real? , 2014 .

[18]  M. Sanders How Do We Know When Something Called "Probiotic" Is Really a Probiotic? A Guideline for Consumers and Health Care Professionals , 2009 .

[19]  J. Leblanc,et al.  Effect of probiotic administration on the intestinal microbiota, current knowledge and potential applications. , 2014, World journal of gastroenterology.

[20]  J. Weese,et al.  Assessment of commercial probiotic bacterial contents and label accuracy. , 2011, The Canadian veterinary journal = La revue veterinaire canadienne.

[21]  Erika Check Hayden Is the $1,000 genome for real? , 2014, Nature.

[22]  Les Dethlefsen,et al.  The Pervasive Effects of an Antibiotic on the Human Gut Microbiota, as Revealed by Deep 16S rRNA Sequencing , 2008, PLoS biology.

[23]  Wenjun Liu,et al.  Comparative Genomic Analysis of 45 Type Strains of the Genus Bifidobacterium: A Snapshot of Its Genetic Diversity and Evolution , 2015, PloS one.

[24]  Glenn R. Gibson,et al.  The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic , 2014 .

[25]  E. Myers,et al.  Basic local alignment search tool. , 1990, Journal of molecular biology.

[26]  S. Piwat,et al.  16S rRNA PCR-Denaturing Gradient Gel Electrophoresis of Oral Lactobacillus casei Group and Their Phenotypic Appearances , 2013, ISRN microbiology.

[27]  B. Chaban,et al.  Lactobacillus casei, Lactobacillus rhamnosus, and Lactobacillus zeae isolates identified by sequence signature and immunoblot phenotype. , 2004, Canadian journal of microbiology.

[28]  M. Adelson,et al.  Evaluation of Five Probiotic Products for Label Claims by DNA Extraction and Polymerase Chain Reaction Analysis , 2005, Digestive Diseases and Sciences.

[29]  S. Chessa,et al.  Genome sequence and analysis of Lactobacillus helveticus , 2013, Front. Microbio..

[30]  Patrick J. Biggs,et al.  SolexaQA: At-a-glance quality assessment of Illumina second-generation sequencing data , 2010, BMC Bioinformatics.

[31]  M. Floch Recommendations for Probiotic Use in Humans—A 2014 Update , 2014, Pharmaceuticals.